Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 18/20 | 0.51 |
| ▸ | FABP3 | P05413 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30317466 | 0.93 | FABP4 (0.49) | FABP4FABP3 | |
| SCHEMBL30398308 | 0.92 | FABP4 (0.48) | FABP4FABP3 | |
| SCHEMBL30317530 | 0.91 | FABP4 (0.47) | FABP4FABP3 | |
| SCHEMBL28983419 | 0.89 | FABP4 (0.46) | FABP4FABP3 | |
| SCHEMBL28983464 | 0.88 | FABP4 (0.46) | FABP4FABP3 | |
| SCHEMBL30317278 | 0.88 | FABP4 (0.46) | FABP4FABP3 | |
| SCHEMBL30317469 | 0.87 | FABP4 (0.50) | FABP4FABP3 | |
| SCHEMBL28983455 | 0.87 | FABP4 (0.50) | FABP4FABP3 | |
| SCHEMBL28983452 | 0.85 | FABP4 (0.60) | FABP4FABP3 | |
| SCHEMBL30317341 | 0.85 | FABP4 (0.60) | FABP4FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116761598-A | Antiviral use of FABP4 modulating compounds | 新月生物科学 | 2023-09-15 | — | — | CN | claimed |
| EP-4175647-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | Crescenta Biosciences (US) | 2023-05-10 | — | — | EP | claimed |
| CN-115803085-A | Novel cell metabolism regulating compounds and uses | 新月生物科学 | 2023-03-14 | — | — | CN | claimed |
| US-12138243-B2 | Antiviral use of FABP4 modulating compounds | CRESCENTA BIOSCIENCES (US) | 2024-11-12 | — | — | US | disclosed |
| CN-116761598-A | Antiviral use of FABP4 modulating compounds | 新月生物科学 | 2023-09-15 | — | — | CN | disclosed |
| EP-4175647-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | Crescenta Biosciences (US) | 2023-05-10 | — | — | EP | disclosed |
| CN-115803085-A | Novel cell metabolism regulating compounds and uses | 新月生物科学 | 2023-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12138243-B2 | Antiviral use of FABP4 modulating compounds | FABP1, FABP5, FABP4 | FABP4 3/4885FABP3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.